Changes in erosion score (A), JSN (B), and mean mTSS (C) at years 2, 6, and 10, and percentage of radiographic nonprogressors (D) over time. Changes in.

Slides:

Advertisements

Similar presentations

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Advertisements

Achieving remission in early RA Dubai, United Arab Emirates 19. January 2009 Professor Joachim Kalden Friedrich-Alexander University Erlangen-Nuremberg.

Septic Arthritis of the Hip Caused by Group B Streptococcus in a Postpartum Patient by Anokhi D. Mehta, Kathleen S. Beebe, Daniel A. Seigerman, John D.

A NEW LOOK AT RA Interactive Hot Topics Series

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Percentage of patients achieving minimal disease activity (MDA): A

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

Percentage of patients achieving DAS28 (CRP) < 3

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Clinical responses over time.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Percentage of applicants and first-time enrollees by race and ethnicity, 2012Note: The number and percentage of applicants and first-time enrollees by.

Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status. Mean change from baseline in disease and.

Percentage of applicants and first-time enrollees by race and ethnicity, 2012–13Note: The number and percentage of applicants and first-time enrollees.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Mean score percentages and standard error bars of the diagnostic test immediately after the learning phase and one week later for integrated basic science.

Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis),

Rats were treated for 21 days ...

MTX-PG concentrations and hepatotoxicity.

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,

Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.

Response rates for patients achieving 50% (A), 70% (B), and 90% (C) improvement in ACR criteria, and normal physical function (D) over the course of 10.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

Patient disposition, weeks 24–128.

A. A. Change from baseline in Genant-modified Sharp total score. B. Erosion score. C. Joint-space narrowing score in patients originally randomized to.

SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations.

Disease Activity at 52 Weeks (ITT population)

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Clinical response in patients with early and established RA at month 24. *p

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.

Percentage of patients with RA achieving DAS28(CRP)<2

A. A. Percentages of patients with active dactylitis in ≥ 4 digits (fingers or toes) at baseline and Week 12. *p < versus baseline. Data are observed.

JSN and SvdH damage and progression scores with and without the CMC3-5 joints. JSN and SvdH damage and progression scores with and without the CMC3-5 joints.

Cumulative changes in mTSS for SB2 and infliximab

Joint damage progression evaluated as a comparison between abatacept plus MTX (grey bar) and placebo plus MTX groups (open bar). Joint damage progression.

JSN incidence of individual joints (left axis) and percentage of individual joints relative to the total number of joints affected by JSN (right axis)

Radiographic endpoints: (A) change from baseline in SHS at Week 52 and Week 104*†; (B) probability plots of change from baseline in SHS at Week 52 and.

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Distribution of swelling and tenderness in joints with or without x-ray progression. Distribution of swelling and tenderness in joints with or without.

Bland and Altman plots showing the JSN progression score difference (y axis) against the mean JSN progression scores (x axis) of the two reading methods.

Malignancy-related events over time for all-bari-RA analysis set (IR).

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Ultrasound examination and conventional radiography of the second proximal interphalangeal joint at baseline (2009) and follow-up (2013). Ultrasound examination.

Patient disposition after 2 years of treatment.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

(A) Mean (95% CI) change and (B) mean percentage (SE) change in enthesitis scores (Leeds Enthesitis Index, SPARCC Enthesitis Index, and MASES) from baseline.

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

All SAE* over time in 5 years.

Fluorescein angiogram of the right eye shows patchy staining of the peripheral retinal veins in the right eye, and nonperfusion of the peripheral retina.

Multivariable model of adjusted

The mTSS individual-patient change from baseline to Week 52 cumulative probability plot (observed data). The mTSS individual-patient change from baseline.

The percentage of patients with baseline BSA ≥ 3% in the ITT population who achieved (a) PASI 75, (c) PASI 90, and (e) PASI 100 during the 24-week double-blind.

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

Two to 20 years: female patients, continued.

Presentation transcript:

Changes in erosion score (A), JSN (B), and mean mTSS (C) at years 2, 6, and 10, and percentage of radiographic nonprogressors (D) over time. Changes in erosion score (A), JSN (B), and mean mTSS (C) at years 2, 6, and 10, and percentage of radiographic nonprogressors (D) over time. Radiographic change (ΔmTSS) probability plots from baseline to year 10 (E), from years 3 to 10 (F). aΔmTSS ≤ 0.5. 10-year completers with radiographic data (n); ADA + MTX = 86; ADA = 85; MTX = 77. MTX: methotrexate; ADA: adalimumab; mTSS: modified total Sharp score; JSN: joint space narrowing. Edward C. Keystone et al. J Rheumatol 2014;41:5-14 ©2014 by The Journal of Rheumatology